← Leaderboards
William F Elmquist
University Of Nebraska Medical Center
$6,030,767
Attributed
$9,998,210
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,998,210 · 8
By mechanism
R01$8,344,627 · 4
U19$1,298,048 · 1
R29$306,600 · 1
R13$48,935 · 2
Top collaborators
- Jann N Sarkaria6 shared
- Peter D Canoll5 shared
- John R Ohlfest5 shared
- Steven S Rosenfeld5 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Oluwatoyin Ajibola Asojo$2,505,382
- Ravi Salgia$9,622,551
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainPharmaceutical PreparationsBrain NeoplasmsTumorEffective TherapyDrug Delivery SystemsNeoplastic CellBaseInhibitor/AntagonistBlood - Brain Barrier AnatomyNovel TherapeuticsMouse ModelGlioblastomaClinical TrialsCellsResponseMediatingEfflux PumpPreventMinnesotaTherapeutic AgentsDrug EffluxRegimenDrug Kinetics
Grant awards (32)
Pharmacology Core$170,572
U19 · FY2025 · CA · contact PI
Pharmacology Core$310,251
U19 · FY2024 · CA · contact PI
Pharmacology Core$372,823
U19 · FY2023 · CA · contact PI
Pharmacology Core$235,362
U19 · FY2022 · CA · contact PI
Targeting Kif11 to Treat Glioblastoma Invasion and Proliferation$560,593
R01 · FY2021 · NS
Pharmacology Core$209,040
U19 · FY2021 · CA · contact PI
Targeting Kif11 to Treat Glioblastoma Invasion and Proliferation$578,057
R01 · FY2020 · NS
2020 Barriers of the CNS GRC/GRS$25,000
R13 · FY2020 · NS · contact PI
Targeting Kif11 to Treat Glioblastoma Invasion and Proliferation$574,526
R01 · FY2019 · NS
2018 Barriers of the CNS Gordon Research Conference and Gordon Research Seminar$23,935
R13 · FY2018 · NS · contact PI
Targeting Kif11 to Treat Glioblastoma Invasion and Proliferation$590,812
R01 · FY2017 · NS
Targeting Kif11 to Treat Glioblastoma Invasion and Proliferation$593,891
R01 · FY2016 · NS
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$493,422
R01 · FY2016 · NS · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$493,574
R01 · FY2015 · NS · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$488,787
R01 · FY2014 · NS · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$297,944
R01 · FY2014 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$476,586
R01 · FY2013 · NS · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$288,640
R01 · FY2013 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$48,893
R01 · FY2013 · NS · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$540,310
R01 · FY2012 · NS · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$306,972
R01 · FY2012 · CA · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$306,884
R01 · FY2011 · CA · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$329,036
R01 · FY2010 · CA · contact PI
Improving the CNS Delivery of Anti-retroviral Compounds$264,826
R01 · FY2007 · NS · contact PI
Improving the CNS Delivery of Anti-retroviral Compounds$272,736
R01 · FY2006 · NS · contact PI
Improving the CNS Delivery of Anti-retroviral Compounds$279,300
R01 · FY2005 · NS
Improving the CNS Delivery of Anti-retroviral Compounds$279,300
R01 · FY2004 · NS
Improving the CNS Delivery of Anti-retroviral Compounds$279,538
R01 · FY2002 · NS
MRP-MEDIATED DRUG TRANSPORT IN THE BBB$54,475
R29 · FY2002 · CA
MRP-MEDIATED DRUG TRANSPORT IN THE BBB$50,645
R29 · FY2002 · CA
MRP-MEDIATED DRUG TRANSPORT IN THE BBB$102,200
R29 · FY2001 · CA
MRP-MEDIATED DRUG TRANSPORT IN THE BBB$99,280
R29 · FY2000 · CA